Section 19-03.1-11 - Schedule IV1. The controlled substances listed in this section are included in schedule IV.2. Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.3. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.b. Dextropropoxyphene (also known as alpha-(+)-4-dimethylamino- 1,2-diphenyl-3-methyl-2-propionoxybutane).c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers including Tramadol.4. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including their salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation: oo. Methylphenobarbital (also known as mephobarbital).5. Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: h. Pemoline (including organometallic complexes and chelates thereof).k. Serdexmethylphenidate.n. SPA ((-)-1-dimethylamino-1, 2-diphenylethane).6. Other substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of: a. Pentazocine, including its salts.b. Butorphanol, including its optical isomers.c. Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.7. The board may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection 2 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.Amended by S.L. 2023 , ch. 210( SB 2093 ), § 2, eff. 4/13/2023.Amended by S.L. 2021 , ch. 173( SB 2059 ), § 4, eff. 4/16/2021.Amended by S.L. 2019 , ch. 185( HB 1113 ), § 5, eff. 4/9/2019.Amended by S.L. 2017 , ch. 163( SB 2096 ), § 3, eff. 3/13/2017.Amended by S.L. 2015 , ch. 169( SB 2100 ), § 3, eff. 3/19/2015.Amended by S.L. 2013 , ch. 184( HB 1070 ), § 3, eff. 3/27/2013.Amended by S.L. 2011 , ch. 161( SB 2119 ), § 4, eff. 8/1/2011.